Phaseline

Companies › Allogene Therapeutics

Allogene Therapeutics: clinical trials, targets and expected readouts

5 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
cemacabtagene ansegedleucel
allogeneic CAR T cell therapy targeting CD19
CD19Phase 2Large B-cell LymphomaDec 2027
ALLO-329
Allogeneic dual CAR T-cell therapy targeting CD19 and CD70
CD19, CD70Phase 1Systemic Lupus Erythematosus (With and Without Nephritis)Feb 2028
ALLO-501A
Anti-CD19 allogeneic CAR T cell therapy
CD19Phase 1Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaFeb 2029
ALLO-316
Allogeneic CAR T cell therapy targeting CD70
CD70Phase 1Advanced/Metastatic Clear Cell Renal Cell CarcinomaJan 2030
ALLO-647
Monoclonal antibody targeting CD52
CD52Phase 1Advanced/Metastatic Clear Cell Renal Cell CarcinomaJan 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06500273cemacabtagene ansegedleucelPhase 2Large B-cell LymphomaOncologyDec 2027
NCT07085104ALLO-329Phase 1Systemic Lupus Erythematosus (With and Without Nephritis)ImmunologyFeb 2028
NCT04416984ALLO-501APhase 1Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaOncologyFeb 2029
NCT04696731ALLO-316Phase 1Advanced/Metastatic Clear Cell Renal Cell CarcinomaOncologyJan 2030
NCT04696731ALLO-647Phase 1Advanced/Metastatic Clear Cell Renal Cell CarcinomaOncologyJan 2030

From the company's SEC filings

Cash and short-term investments of $389m on 2026-09-30; operating cash outflow about $109m a year; runway about 43 months at that burn, to Apr 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

CD19 (3) CD70 (2) CD52 (1)

Companies with the same targets

Chongqing Precision Biotech Gilead Sciences Bristol-Myers Squibb Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics ImmunityBio

Companies built like this

Erasca Takara Bio Bicara Therapeutics Fate Therapeutics OncoVerity

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.